Equasens: annual sales growth of almost 3%

(CercleFinance.com) - Equasens reports sales for 2023 up 2.
6% to ?219.7 million (+3.3% on a like-for-like basis), 'despite an unfavorable base effect linked to the Ségur and a difficult economic climate, particularly in the pharmaceuticals market'.

In the fourth quarter of last year alone, the healthcare software solutions group saw its sales fall to 57 million euros (-5.5% versus the last quarter of 2022, but +0.4% on a like-for-like basis).

"The macro-economic environment looks more favorable in 2024, with a decline in inflation, lower financing rates and an expected upturn in pharmacy activity in the first half of the year", it stresses, however.

Copyright (c) 2024 CercleFinance.com. All rights reserved.